A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

May 2, 2030

Study Completion Date

May 2, 2030

Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
DRUG

BMS-986453

Specified dose on specified days

DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide

Specified dose on specified days

Trial Locations (19)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

33612

RECRUITING

Moffitt Cancer Center, Tampa

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

37007

RECRUITING

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca

37203

NOT_YET_RECRUITING

Local Institution - 0008, Nashville

RECRUITING

Tennessee Oncology, Nashville

50937

RECRUITING

Universitaetsklinikum Koeln, Cologne

75010

RECRUITING

Hôpital Saint-Louis, Paris

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

94143

RECRUITING

UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

94305

RECRUITING

Stanford University Medical Center, Stanford

97080

RECRUITING

Universitaetsklinikum Wuerzburg, Würzburg

98104

RECRUITING

Swedish Medical Center, Seattle

06520

RECRUITING

Yale Cancer Center, New Haven

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

D-69120

RECRUITING

Universitaetsklinikum Heidelberg, Heidelberg

All Listed Sponsors
lead

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY